Approval Year
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000182830
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
||
|
WHO-ATC |
L04AA28
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
||
|
NCI_THESAURUS |
C574
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
NULOJIX (AUTHORIZED: GRAFT REJECTION)
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
NULOJIX (AUTHORIZED: KIDNEY TRANSPLANTATION)
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
||
|
FDA ORPHAN DRUG |
253907
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
||
|
WHO-VATC |
QL04AA28
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
N0000182829
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
PRIMARY | T Lymphocyte Costimulation Activity Blockade [PE] | ||
|
5091
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
PRIMARY | |||
|
QQ-105
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
PRIMARY | |||
|
E3B2GI648A
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
PRIMARY | |||
|
1112973
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
PRIMARY | RxNorm | ||
|
706808-37-9
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
PRIMARY | |||
|
N0000182151
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
PRIMARY | CD86-directed Antibody Interactions [MoA] | ||
|
CHEMBL1742990
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
PRIMARY | |||
|
100000092978
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
PRIMARY | |||
|
C80255
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
PRIMARY | |||
|
DB06681
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
PRIMARY | |||
|
6892
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
PRIMARY | |||
|
Belatacept
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
PRIMARY | |||
|
BELATACEPT
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
PRIMARY | |||
|
N0000182150
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
PRIMARY | CD80-directed Antibody Interactions [MoA] | ||
|
m2293
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB20603
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
PRIMARY | |||
|
8627
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
PRIMARY | |||
|
E3B2GI648A
Created by
admin on Fri Dec 15 17:28:30 GMT 2023 , Edited by admin on Fri Dec 15 17:28:30 GMT 2023
|
PRIMARY |
ACTIVE MOIETY